Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Transcat (TRNS) Shares Outstanding (Weighted Average) (2016 - 2025)

Transcat (TRNS) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $9.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.07% to $9.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.3 million through Dec 2025, up 1.07% year-over-year, with the annual reading at $9.2 million for FY2025, 11.48% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $9.3 million in Q4 2025 for Transcat, roughly flat from $9.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $9.3 million in Q4 2025 to a low of $7464.0 in Q2 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $7.9 million across 5 years, with a median of $7.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 99.9% in 2021 and later soared 100851.23% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $7.5 million in 2021, then rose by 0.37% to $7.5 million in 2022, then increased by 14.15% to $8.6 million in 2023, then increased by 7.14% to $9.2 million in 2024, then grew by 1.07% to $9.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TRNS at $9.3 million in Q4 2025, $9.3 million in Q3 2025, and $9.3 million in Q2 2025.